statistiche ricercatore

Nome	#
Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel	273
Impact of safety-related dose reductions or discontinuations on sustained virologic response in HCV-infected patients: Results from the GUARD-C Cohort	271
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study	193
Modeling cost-effectiveness and health gains of a âuniversalâ versus âprioritizedâ hepatitis C virus treatment policy in a real-life cohort	185
Missed treatment in an Italian HBV infected patients cohort: HBV RER	184
From current status to optimization of HCV treatment: Recommendations from an expert panel	158
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis	116
What to start with in first line treatment of chronic hepatitis B patients: an Italian multicentre observational cohort, HBV-RER study group	95
CFD analysis of compensator for meter out sensing system	82
Totale	1.557

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2019/2020	301	24	6	5	16	33	79	50	25	32	9	18	4
2020/2021	459	24	14	44	56	43	65	96	34	24	22	26	11
2021/2022	209	16	10	9	18	3	9	15	19	18	21	42	29
2022/2023	221	26	32	24	29	27	29	2	14	22	0	11	5
2023/2024	111	6	8	12	11	11	12	11	11	2	4	3	20
2024/2025	15	15	0	0	0	0	0	0	0	0	0	0	0
Totale													1.557